器官移植中耐碳青霉烯类肺炎克雷伯菌感染的研究进展  

Research progress on carbapenem-resistant Klebsiella pneumoniae infection in organ transplantation

作　　者：刘伟旺 王晓[2] 李传昶[1] Liu Weiwang;Wang Xiao;Li Chuanchang(Department of Geriatrics,Xiangya Hospital of Central South University,Changsha 410008,China)

机构地区：[1]中南大学湘雅医院老年病科,长沙410008 [2]广东省第二人民医院器官移植科

出　　处：《器官移植》2020年第3期405-412,共8页Organ Transplantation

基　　金：国家自然科学基金面上项目(81873509)。

摘　　要：肺炎克雷伯菌(KP)是一种常见的条件致病菌,也是引起免疫功能低下患者感染常见的病原菌之一,其感染率呈逐年递增的趋势。碳青霉烯类抗生素是控制KP感染的有效药物,但随着碳青酶烯类抗生素的广泛使用,耐碳青霉烯类肺炎克雷伯菌(CRKP)出现并逐年增长。器官移植受者由于免疫系统受抑制,是CRKP感染的高危人群,一旦发生耐药菌感染,往往难以控制,导致移植器官存活率降低,给临床治疗带来巨大的挑战。本文就器官移植中CRKP感染的现状、治疗进展作一综述。Klebsiella pneumoniae(KP)is a common conditional pathogen,and also one of the common pathogens causing infection in immunocompromised patients,with its infection rate increasing year by year.Carbapenem antibiotics are effective drugs to control KP infection.But with the widespread use of carbapenem antibiotics,carbapenemresistant Klebsiella pneumoniae(CRKP)appears and increases year by year.Organ transplant recipients are at high risk of CRKP infection due to the suppressed immune system.Once drug-resistant bacteria infection occurs,it is often difficult to control and the survival rate of transplant organs is reduced,which brings great challenges to clinical treatment.In this article,the current status and treatment progress of CRKP infection in organ transplantation are summarized.

关 键 词：器官移植 耐碳青霉烯类肺炎克雷伯菌 感染 心脏死亡器官捐献 移植物功能延迟恢复 重症监护室 头孢他啶-阿维巴坦 噬菌体 

分 类 号：R617[医药卫生—外科学] R378.2[医药卫生—临床医学]